A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models

Neoplasia (United States)

Volumn 20, Issue 8, 2018, Pages 789-799

  Mamouni, Kenza ^a   Zhang, Shumin ^b   Li, Xin ^a   Chen, Yanhua ^a   Yang, Yang ^a   Kim, Jaeah ^c   Bartlett, Michael G ^c   Coleman, Ilsa M ^d   Nelson, Peter S ^d   Kucuk, Omer ^b   Wu, Daqing ^a,b,e  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e MetCure Therapeutics LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; DOCETAXEL; ENZALUTAMIDE; KAEMPFEROL; LUTEOLIN; PROFINE; QUERCETIN; SURVIVIN; TRANSCRIPTOME; UNCLASSIFIED DRUG; ANDROGEN; AR PROTEIN, HUMAN; FLAVONOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE ATROPHY; BONE MICROARCHITECTURE; CANCER INHIBITION; CHEMICAL COMPOSITION; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUVEC CELL LINE; IC50; IN VITRO STUDY; IN VIVO STUDY; LNCAP C4-2 CELL LINE; MALE; MEDIAN SURVIVAL TIME; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRECLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; SURVIVAL RATE; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; METABOLISM; NUDE MOUSE; PROCEDURES; PROSTATE TUMOR; TUMOR CELL LINE;

ANDROGENS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FLAVONOIDS; HUMANS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85049860330     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2018.06.003     Document Type: Article

References (53)

1. Siegel, RL, Miller, KD, Jemal, A, Cancer statistics, 2018. CA Cancer J Clin 68 (2018), 7–30.
2. Van der Kwast, TH, Roobol, MJ, Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol 10 (2013), 473–482.
3. Prostate Cancer, Nutrition, and Dietary Supplements (PDQ(R)): Health Professional Version. 2002, National Cancer Institute online publication, Bethesda (MD) (https://www.cancer.gov/about-cancer/treatment/cam/hp/prostate-supplements-pdq).
4. Kallifatidis, G, Hoy, JJ, Lokeshwar, BL, Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer. Semin Cancer Biol 40-41 (2016), 160–169.
5. Thomas, R, Williams, M, Sharma, H, Chaudry, A, Bellamy, P, A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer-the UK NCRN Pomi-T study. Prostate Cancer Prostatic Dis 17 (2014), 180–186.
6. Kozlowska, A, Szostak-Wegierek, D, Flavonoids—food sources and health benefits. Rocz Panstw Zakl Hig 65 (2014), 79–85.
7. Hollman, PC, Katan, MB, Health effects and bioavailability of dietary flavonols. Free Radic Res 31 Suppl (1999), S75–S80.
8. Weng, CJ, Yen, GC, Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo anti-metastatic activities. Cancer Metastasis Rev 31 (2012), 323–351.
9. Korbakis, D, Gregorakis, AK, Scorilas, A, Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: an independent cancer biomarker. Clin Chem 55 (2009), 904–913.
10. Mavridis, K, Talieri, M, Scorilas, A, KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone. Biol Chem 391 (2010), 467–474.
11. Bieberich, CJ, Fujita, K, He, WW, Jay, G, Prostate-specific and androgen-dependent expression of a novel homeobox gene. J Biol Chem 271 (1996), 31779–31782.
12. Lin, B, Ferguson, C, White, JT, Wang, S, Vessella, R, True, LD, Hood, L, Nelson, PS, Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 59 (1999), 4180–4184.
13. Young, CY, Montgomery, BT, Andrews, PE, Qui, SD, Bilhartz, DL, Tindall, DJ, Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 51 (1991), 3748–3752.
14. Xu, LL, Shanmugam, N, Segawa, T, Sesterhenn, IA, McLeod, DG, Moul, JW, Srivastava, S, A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate. Genomics 66 (2000), 257–263.
15. Wang, Z, Yan, C, Emerging roles of ATF3 in the suppression of prostate cancer. Mol Cell Oncol, 3, 2016, e1010948.
16. Wang, J, Zhang, W, Ji, W, Liu, X, Ouyang, G, Xiao, W, The von hippel-lindau protein suppresses androgen receptor activity. Mol Endocrinol 28 (2014), 239–248.
17. Seo, SI, Gera, L, Zhau, HE, Qian, WP, Iqbal, S, Johnson, NA, Zhang, S, Zayzafoon, M, Stewart, J, Wang, R, et al. BKM1740, an acyl-tyrosine bisphosphonate amide derivative, inhibits the bone metastatic growth of human prostate cancer cells by inducing apoptosis. Clin Cancer Res 14 (2008), 6198–6206.
18. Wu, K, Gore, C, Yang, L, Fazli, L, Gleave, M, Pong, RC, Xiao, G, Zhang, L, Yun, EJ, Tseng, SF, et al. Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer. Mol Endocrinol 26 (2012), 1496–1507.
19. Chen, L, Li, J, Farah, E, Sarkar, S, Ahmad, N, Gupta, S, Larner, J, Liu, X, Cotargeting HSP90 and its client proteins for treatment of prostate cancer. Mol Cancer Ther 15 (2016), 2107–2118.
20. Zhao, J, Tenev, T, Martins, LM, Downward, J, Lemoine, NR, The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci 113:Pt 23 (2000), 4363–4371.
21. Gritsko, T, Williams, A, Turkson, J, Kaneko, S, Bowman, T, Huang, M, Nam, S, Eweis, I, Diaz, N, Sullivan, D, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12 (2006), 11–19.
22. de Brot, S, Ntekim, A, Cardenas, R, James, V, Allegrucci, C, Heery, DM, Bates, DO, Odum, N, Persson, JL, Mongan, NP, Regulation of vascular endothelial growth factor in prostate cancer. Endocr Relat Cancer 22 (2015), R107–R123.
23. Luo, H, Jiang, BH, King, SM, Chen, YC, Inhibition of cell growth and VEGF expression in ovarian cancer cells by flavonoids. Nutr Cancer 60 (2008), 800–809.
24. Lee, DH, Lee, YJ, Quercetin suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha) through inhibiting protein synthesis. J Cell Biochem 105 (2008), 546–553.
25. Sak, K, Cytotoxicity of dietary flavonoids on different human cancer types. Pharmacogn Rev 8 (2014), 122–146.
26. Chen, X, Liu, L, Sun, Z, Liu, Y, Xu, J, Liu, S, Huang, B, Ma, L, Yu, Z, Bi, K, Pharmacokinetics of luteolin and tetra-acetyl-luteolin assayed by HPLC in rats after oral administration. Biomed Chromatogr 24 (2010), 826–832.
27. Dong, X, Lan, W, Yin, X, Yang, C, Wang, W, Ni, J, Simultaneous determination and pharmacokinetic study of quercetin, luteolin, and apigenin in rat plasma after oral administration of Matricaria chamomilla L. extract by HPLC-UV. Evid Based Complement Alternat Med, 2017, 2017, 8370584.
28. Barve, A, Chen, C, Hebbar, V, Desiderio, J, Saw, CL, Kong, AN, Metabolism, oral bioavailability and pharmacokinetics of chemopreventive kaempferol in rats. Biopharm Drug Dispos 30 (2009), 356–365.
29. Kim, TH, Jung, JW, Ha, BG, Hong, JM, Park, EK, Kim, HJ, Kim, SY, The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss. J Nutr Biochem 22 (2011), 8–15.
30. Liang, W, Luo, Z, Ge, S, Li, M, Du, J, Yang, M, Yan, M, Ye, Z, Luo, Z, Oral administration of quercetin inhibits bone loss in rat model of diabetic osteopenia. Eur J Pharmacol 670 (2011), 317–324.
31. Yang, L, Takai, H, Utsunomiya, T, Li, X, Li, Z, Wang, Z, Wang, S, Sasaki, Y, Yamamoto, H, Ogata, Y, Kaempferol stimulates bone sialoprotein gene transcription and new bone formation. J Cell Biochem 110 (2010), 1342–1355.
32. Neuhouser, ML, Dietary flavonoids and cancer risk: evidence from human population studies. Nutr Cancer 50 (2004), 1–7.
33. Tena, JD, Burgos-Morón, E, Calderón-Montaño, JM, Sanz, I, Sainz, J, Lopez-Lazaro, M, Consumption of the dietary flavonoids quercetin, luteolin and kaempferol and overall risk of cancer — a review and meta-analysis of the epidemiological data. WebmedCentral CANCER, 4, 2013, WMC004264.
34. Guo, K, Liang, Z, Liu, L, Li, F, Wang, H, Flavonoids intake and risk of prostate cancer: a meta-analysis of observational studies. Andrologia 48 (2016), 1175–1182.
35. Chiu, FL, Lin, JK, Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. Prostate 68 (2008), 61–71.
36. Hashemzaei, M, Delarami Far, A, Yari, A, Heravi, RE, Tabrizian, K, Taghdisi, SM, Sadegh, SE, Tsarouhas, K, Kouretas, D, Tzanakakis, G, et al. Anticancer and apoptosisinducing effects of quercetin in vitro and in vivo. Oncol Rep 38 (2017), 819–828.
37. Dang, Q, Song, W, Xu, D, Ma, Y, Li, F, Zeng, J, Zhu, G, Wang, X, Chang, LS, He, D, et al. Kaempferol suppresses bladder cancer tumor growth by inhibiting cell proliferation and inducing apoptosis. Mol Carcinog 54 (2015), 831–840.
38. Luo, H, Rankin, GO, Liu, L, Daddysman, MK, Jiang, BH, Chen, YC, Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells. Nutr Cancer 61 (2009), 554–563.
39. Li, Y, Ahmad, A, Kong, D, Bao, B, Sarkar, FH, Recent progress on nutraceutical research in prostate cancer. Cancer Metastasis Rev 33 (2014), 629–640.
40. Fu, J, Chen, D, Zhao, B, Zhao, Z, Zhou, J, Xu, Y, Xin, Y, Liu, C, Luo, L, Yin, Z, Luteolin induces carcinoma cell apoptosis through binding Hsp90 to suppress constitutive activation of STAT3. PLoS One, 7, 2012, e49194.
41. Stope, MB, Schubert, T, Staar, D, Ronnau, C, Streitborger, A, Kroeger, N, Kubisch, C, Zimmermann, U, Walther, R, Burchardt, M, Effect of the heat shock protein HSP27 on androgen receptor expression and function in prostate cancer cells. World J Urol 30 (2012), 327–331.
42. Hansen, RK, Oesterreich, S, Lemieux, P, Sarge, KD, Fuqua, SA, Quercetin inhibits heat shock protein induction but not heat shock factor DNA-binding in human breast carcinoma cells. Biochem Biophys Res Commun 239 (1997), 851–856.
43. Yamamoto, T, Sato, N, Sekine, Y, Yumioka, T, Imoto, S, Junicho, A, Fuse, H, Matsuda, T, Molecular interactions between STAT3 and protein inhibitor of activated STAT3, and androgen receptor. Biochem Biophys Res Commun 306 (2003), 610–615.
44. Manach, C, Williamson, G, Morand, C, Scalbert, A, Remesy, C, Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81 (2005), 230S–242S.
45. Del Rio, D, Rodriguez-Mateos, A, Spencer, JP, Tognolini, M, Borges, G, Crozier, A, Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid Redox Signal 18 (2013), 1818–1892.
46. Balentine, DA, Dwyer, JT, Erdman, JW Jr., Ferruzzi, MG, Gaine, PC, Harnly, JM, Kwik-Uribe, CL, Recommendations on reporting requirements for flavonoids in research. Am J Clin Nutr 101 (2015), 1113–1125.
47. Sachs, JR, Mayawala, K, Gadamsetty, S, Kang, SP, de Alwis, DP, Optimal dosing for targeted therapies in oncology: drug development cases leading by example. Clin Cancer Res 22 (2016), 1318–1324.
48. Lippman, SM, Klein, EA, Goodman, PJ, Lucia, MS, Thompson, IM, Ford, LG, Parnes, HL, Minasian, LM, Gaziano, JM, Hartline, JA, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301 (2009), 39–51.
49. Cai, H, Scott, E, Kholghi, A, Andreadi, C, Rufini, A, Karmokar, A, Britton, RG, Horner-Glister, E, Greaves, P, Jawad, D, et al. Cancer chemoprevention: evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice. Sci Transl Med, 7, 2015, 298ra117.
50. Murakami, A, Dose-dependent functionality and toxicity of green tea polyphenols in experimental rodents. Arch Biochem Biophys 557 (2014), 3–10.
51. Gaya, A, Akle, CA, Mudan, S, Grange, J, The concept of hormesis in cancer therapy — is less more?. Cureus, 7, 2015, e261.
52. Wilt, TJ, Jones, KM, Barry, MJ, Andriole, GL, Culkin, D, Wheeler, T, Aronson, WJ, Brawer, MK, Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med 377 (2017), 132–142.
53. Hamdy, FC, Donovan, JL, Lane, JA, Mason, M, Metcalfe, C, Holding, P, Davis, M, Peters, TJ, Turner, EL, Martin, RM, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375 (2016), 1415–1424.